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Maria C. Nunes, MD, PhD; Luis M. Rincon, MD; David M. Shahian, MD; Michael H. Picard, MD; Jonathan Aﬁlalo, MD, MSc
Background-—Risk prediction is a critical step in patient selection for aortic valve replacement (AVR), yet existing risk scores
incorporate very few echocardiographic parameters. We sought to evaluate the incremental predictive value of a complete
echocardiogram to identify high-risk surgical candidates before AVR.
Methods and Results-—A cohort of patients with severe aortic stenosis undergoing surgical AVR with or without coronary bypass
was assembled at 2 tertiary centers. Preoperative echocardiograms were reviewed by independent observers to quantify chamber
size/function and valve function. Patient databases were queried to extract clinical data. The cohort consisted of 432 patients with
a mean age of 73.5 years and 38.7% females. Multivariable logistic regression revealed 3 echocardiographic predictors of in-
hospital mortality or major morbidity: E/e’ ratio reﬂective of elevated left ventricular (LV) ﬁlling pressure; myocardial performance
index reﬂective of right ventricular (RV) dysfunction; and small LV end-diastolic cavity size. Addition of these echocardiographic
parameters to the STS risk score led to an integrated discrimination improvement of 4.1% (P<0.0001). After a median follow-up of
2 years, Cox regression revealed 5 echocardiographic predictors of all-cause mortality: small LV end-diastolic cavity size; LV mass
index; mitral regurgitation grade; right atrial area index; and mean aortic gradient <40 mm Hg.
Conclusions-—Echocardiographic measures of LV diastolic dysfunction and RV performance add incremental value to the STS risk
score and should be integrated in prediction when evaluating the risk of AVR. In addition, ﬁndings of small hypertrophied LV
cavities and/or low mean aortic gradients confer a higher risk of 2-year mortality. ( J Am Heart Assoc. 2015;4:e002129 doi:
10.1161/JAHA.115.002129)
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A ortic stenosis (AS) is one of the most common valvularheart diseases with a pooled prevalence of 12.4% in
older adults.1 Severe AS has been identiﬁed as a major cause
of morbidity and mortality and, if untreated, can result in
debilitating clinical symptoms, progressive heart failure, and
sudden cardiac death. The economic impact of AS on the
health care system is substantial.2 Traditionally, surgical
aortic valve replacement (SAVR) has been the mainstay of
treatment for severe AS, but has been associated with 3.2% to
5.6% perioperative mortality when performed without and with
concomitant coronary artery bypass graft surgery (CABG),
respectively.3,4 In high-risk elderly patients, the risk of
mortality approaches 10%, and 1 of 3 of these patients’
experiences a major morbidity.3,4 A contributing factor to the
adverse outcomes observed is that many of the elderly
patients considered for SAVR are frail and have multiple
chronic conditions.5
The emergence of therapeutic alternatives to surgery, such
as transcatheter aortic valve replacement (TAVR), has
provided a treatment alternative for a signiﬁcant number of
patients with severe AS and high surgical risk, usually deﬁned
as a predicted risk of mortality >8% to 10%.6 Approximately
290 000 elderly patients at high surgical risk could potentially
be treated with TAVR in Europe and North America.1 Hence,
the signiﬁcance of operative risk prediction has increased
dramatically owing to its importance in guiding therapeutic
decision making in patients with severe AS. Clinicians and
researchers rely on risk scores such as The Society of
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Thoracic Surgeons (STS) Predicted Risk and the European
System for Cardiac Operative Risk Evaluation (EuroSCORE) to
estimate risk, although it is recognized that these scores do
not capture a number of important variables.
At the present time, risk scores integrate very few
echocardiographic variables in their calculations, typically
limited to left ventricular (LV) ejection fraction (LVEF), mitral
regurgitation (MR) grade, and pulmonary artery systolic
pressure (PASP). This represents a missed opportunity to
enhance risk prediction given the wealth of hemodynamic,
functional, and structural data available in routinely performed
preoperative echocardiograms. Recently, our group demon-
strated the incremental prognostic value of preoperative
echocardiograms in patients undergoing isolated CABG.7
Thus, we expanded this hypothesis to patients undergoing
SAVR to determine the incremental prognostic value of the
echocardiogram in addition to the STS risk score to predict
short- and long-term mortality and major morbidity.
Methods
Study Design
A cohort of consecutive patients undergoing SAVR with or
without CABG at 2 tertiary referral hospitals in the United
States and Canada was assembled. Preoperative echocardio-
grams were analyzed by 2 independent observers who were
blinded to the outcomes. A comprehensive echocardiographic
protocol was quantitatively measured, reﬂecting right- and
left-sided chamber size and geometry, systolic and diastolic
function of the right and left ventricles, and valvular hemo-
dynamics. Clinical variables were extracted from patient
databases and vital status from the Social Security Registry.
The study was approved by the institutional review board
before commencement, and the manuscript was prepared in
accord with the Strengthening of Reporting of Observational
Studies in Epidemiology guidelines.8
Setting
The cohort consisted of consecutive patients who underwent
isolated SAVR or combined SAVR+CABG at the Mas-
sachusetts General Hospital between 2008 and 2010 (Har-
vard University, Boston, MA) and at the Jewish General
Hospital between 2010 and 2012 (McGill University, Mon-
treal, Quebec, Canada). Both hospitals are academic centers
with access to TAVR (although TAVR was in its early stages of
adoption and limited to research protocols during the time
frame of this study). Patients were followed from the time of
their index admission to hospital discharge and subsequently
followed forward for vital status up to February 2013.
Participants
The inclusion criteria were: (1) severe AS deﬁned as a peak
velocity ≥4 m/s, mean gradient ≥40 mm Hg, aortic valve
area (AVA) <1.0 cm2, or indexed AVA <0.6 cm2/m2 by
Doppler echocardiography in combination with 2-dimensional
echocardiographic appearance of severe valvular AS; (2) SAVR
performed with or without CABG; (3) preoperative transtho-
racic echocardiogram (TTE) performed at the study center
≤3 months before surgery. Patients who had concomitant
mitral or tricuspid valve surgery, greater than moderate aortic
regurgitation, previous valvuloplasty or valve replacement, or
complex congenital heart disease were excluded. Patient who
had surgical intervention on the aorta were not excluded.
Because echocardiographic images were reanalyzed for the
purpose of this study, patients were excluded if their digital
echocardiographic images could not be retrieved or were
uninterpretable.
Predictor Variables
A comprehensive list of quantitative parameters of left- and
right-sided chamber size, geometry, systolic and diastolic
function, and valvular function was established a priori and
then measured from the preoperative echocardiograms. The
acquisitions, measurements, and normal reference limits
adhered to the guidelines of the American Society of
Echocardiography (ASE).9–13 Right and left atrial areas were
measured at end-systole in the apical 4-chamber view; left
atrial height was also measured to calculate left atrial
volume using the single-plane area-length method. Right
ventricular (RV) area was measured at end-diastole and end-
systole in the apical 4-chamber view to calculate fractional
area change (FAC) as: [RV end-diastolic areaRV end-
systolic area]/[RV end-diastolic area]. Tricuspid valve closure
to opening time was measured by continuous-wave Doppler
of the tricuspid regurgitation and/or pulsed Doppler of the
tricuspid inﬂow. Pulmonic ejection time was measured from
pulsed Doppler proﬁles obtained at the distal RV outﬂow
tract. RV myocardial performance index (MPI), an index of
RV efﬁciency reﬂecting both systolic and diastolic function,
was calculated as: [Tricuspid valve closure opening
timePulmonic ejection time]/[Pulmonic ejection time].
PASP was measured by continuous-wave Doppler of the
tricuspid regurgitation with 10 mm Hg added for right atrial
pressure. The choice of parameters was conﬁned to those
that could be measured from the routine echocardiography
protocol at both institutions; for example, tricuspid annular
plane systolic excursion and/or velocity were not included in
our panel because they were not routinely acquired in all
patients.
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LVEF and LV volumes were measured using the biplane
Simpson’s method. LV mass was measured using the
Devereux method. LV diastolic function was graded as
normal, impaired relaxation, pseudonormal ﬁlling, or restric-
tive ﬁlling according to the ASE’s recommended multipara-
metric approach that integrates pulsed Doppler of the mitral
and pulmonary vein inﬂow, tissue Doppler of the medial and
lateral annulus, and left atrial volume. Valvular regurgitation
was graded as normal, mild, moderate, or severe according to
the ASE’s recommended cutoffs for color Doppler jet area,
vena contracta diameter, and proximal isovelocity shell area,
where applicable. Measures of AS severity included peak
velocity, peak and mean gradients, dimensionless index
calculated as [LV outﬂow tract (LVOT) velocity/Peak velocity],
AVA using velocity time integrals rather than velocities, and
AVA indexed to body surface area.
Measurements were performed in duplicate by 2 indepen-
dent echocardiography readers and arbitrated by a third
senior reader. All readers were cardiologists trained in
echocardiography. To ensure accuracy and consistency of
measurement techniques, readers participated in focused
training sessions and quality audits throughout the study.
Readers were blinded to the clinical data and outcomes when
interpreting the echocardiograms.
Outcome Variables
The primary outcome was a composite of in-hospital mortality
or major morbidity deﬁned according to the STS as any one of
the following: all-cause death, stroke, renal failure (Risk,
Injury, Failure, Loss of kidney function, and End-stage kidney
disease [RIFLE] classiﬁcation ≥3), prolonged ventilation
≥48 hours, or need for reoperation.14 The secondary outcome
was long-term all-cause mortality deﬁned as death from any
cause occurring from the time of cardiac surgery to the end of
follow-up. There were no patients lost to follow-up for the
primary or secondary outcomes.
Data Sources
Echocardiograms were acquired with the Philips IE33, Sonos
7500, or GE Vivid 7 machines and analyzed on the Xcelera
workstation (Philips Medical Systems, Andover, MA) at the
Massachusetts General Hospital; and with the GE Vivid 7
machine and EchoPAC workstation (GE, Milwaukee, WI) at the
Jewish General Hospital. Clinical data, including in-hospital
outcomes, were extracted from the STS Adult Cardiac Surgery
Database and vital status was extracted from the Social
Security Death Index by way of the Research Patient
Data Registry (Partners Healthcare, Boston, MA) at the
Massachusetts General Hospitals; and from the ChartMaxx
electronic medical record at the Jewish General Hospital.
Statistical Analyses
Echocardiography variables were preserved in their continu-
ous form15 and standardized such that the resulting odds
ratios (ORs) represented the increase in odds per SD in that
variable. To test the appropriateness of entering a continuous
variable in a logistic regression model, each echocardio-
graphic variable (x-axis) was plotted against the logit of the
primary outcome (y-axis) and the resulting graphical plot was
inspected for linearity. When a nonlinear relationship was
observed, the variable was transformed into ordinal form.
For the primary outcome, multivariable logistic regression
with Akaike information criterion (AIC)-based model selection
was used to identify the optimal echocardiographic parame-
ters to predict in-hospital mortality or major morbidity after
adjusting for the STS predicted risk of mortality or major
morbidity (STS-PROMM). For the secondary outcome, multi-
variable Cox regression with AIC-based model selection was
used to identify the optimal echocardiographic parameters to
predict all-cause mortality after adjusting for the Society of
Thoracic Surgeons predicted risk of mortality (STS-PROM).
The AIC model selection procedure approximates a backward-
forward selection procedure with a P-value cutoff of 0.15,
hence the optimal predictors may have conﬁdence intervals
(CIs) that cross unity.
Model performance statistics were calculated for STS-
PROM (or STS-PROMM) alone, and then for STS-PROM (or
STS-PROMM) plus the echocardiographic variables. These
statistics included the c-statistic and integrated discrimina-
tion improvement (IDI).16 All analyses were performed with
the STATA 13 statistical software package (StataCorp LP,
College Station, TX).
Results
A total of 1144 patients underwent SAVR at both sites during
the study period, of which 432 were eligible and included in
the cohort (Figure). The main exclusion criterion was not
having an available echocardiogram ≤3 months before
surgery; excluded patients who did not have an available
echocardiogram were similar to included patients in terms of
mean age (73.9 vs. 73.5 years), proportion of females (41.1%
vs. 38.7%), STS-PROM (5.5% vs. 5.3%), and observed in-
hospital mortality (3.2% vs. 3.2%). The median time from
echocardiography to surgery was 13 days (interquartile range
[IQR], 6–43). The median time from surgery to end of follow-
up was 728 days (IQR, 354–1063).
Baseline clinical characteristics are shown in Table 1 and
in-hospital outcomes are shown in Table 2. The mean age of
the cohort was 73.510.3 years, with 38.7% females. The
surgical procedure was isolated SAVR in 49.3% and combined
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SAVR/CABG in 50.7%. The mean STS-PROM was 5.35.1%,
and STS-PROMM was 25.714.1%. There were 45 deaths and
88 composite adverse events observed (20.4% in-hospital
mortality or major morbidity). Adverse event rates were
similar at both study centers. Those who had an adverse
event were more likely to have advanced age, female sex,
chronic kidney disease, and recently decompensated heart
failure.
Preoperative echocardiographic parameters are shown in
Table 3. AS severity was reﬂected by AVA 0.750.22 cm2,
indexed AVA 0.390.11 cm2/m2, and peak and mean
gradients of 79.6 and 52.7 mm Hg, respectively. One
hundred ten patients had severe AS with low mean gradient
<40 mm Hg, of which 10.2% had low LVEF <35%. The
prevalence of RV systolic dysfunction (abnormal FAC) was
14.4%, whereas subclinical RV dysfunction (abnormal RV MPI
with normal RV FAC) was 45.2%. The prevalence of LV
hypertrophy was 52.3% and small LV end-diastolic volume
index (LVEDVi) was 9.3%.
In the logistic regression model to predict in-hospital
mortality or major morbidity, 3 echocardiographic parame-
ters were independently predictive after adjusting for STS-
PROMM (Table 4): E/e’ (standardized OR, 1.40; 95% CI,
1.03, 1.78), RV MPI (OR, 1.25; 95% CI, 0.94, 1.65), and
LVEDVi (OR, 0.82; 95% CI, 0.54, 1.00). Model performance
was signiﬁcantly improved by addition of these 3 echocar-
diographic parameters to the STS-PROMM, resulting in an
IDI of 4.1% (P<0.001) and an increase in c-statistic from
0.70 for STS-PROMM alone to 0.74 for STS-PROMM plus
echocardiographic parameters. The IDI was driven mainly by
the new model predicting a higher risk in patients that
experienced an adverse event.
A Cox model was then used to predict long-term all-
cause mortality at the median follow-up of 2 years
(maximum of 4.2 years), and 5 echocardiographic param-
eters were independently predictive after adjusting for
STS-PROM (Table 5): LV mass index (standardized hazard
ratio [HR], 1.38; 95% CI, 1.03, 1.91), RA area index (HR,
1.28; 95% CI, 0.94, 1.70), mean aortic gradient
<40 mm Hg (HR, 2.23; 95% CI, 1.04, 4.76), mitral
regurgitation grade (HR, 1.45; 95% CI, 0.97, 2.16), and
LVEDVi (HR, 0.54; 95% CI, 0.35, 0.82). Addition of these
echocardiographic parameters led to an increase in
Harrell’s c-statistic from 0.82 for STS-PROM alone to
0.85 for STS-PROM plus echocardiographic parameters.
In sensitivity analyses, regression models were rerun with
bootstrapping (1000 repetitions); these models identiﬁed the
same echocardiographic optimal predictors and yielded
similar effect sizes for each predictor. The intervariable
correlation between the echocardiographic parameters
included in the adjusted multivariable models was low (R,
0.02–0.31).
Discussion
Our 2-center study has shown that the preoperative echocar-
diogram contributes incremental value to identify high-risk
candidates for SAVR. In particular, small LV cavity size, LV
diastolic dysfunction (high E/e’ ratio), and RV dysfunction
(high RV MPI) were identiﬁed as powerful predictors of in-
hospital mortality and major morbidity after SAVR. Enlarged
RA cavity size, small LV cavity size, LV hypertrophy, MR, and
low mean aortic gradient <40 mm Hg were predictive of long-
term mortality over a median follow-up period of 2 years.
None of these echocardiographic parameters are currently
considered in risk scores for patient selection in AVR.
The magnitude of the incremental value provided by the
echocardiogram is important, comparable to other well-
Figure. Flow diagram. Of 1144 patients that underwent SAVR
with or without CABG, 432 met the selection criteria and were
included in the cohort. Excluded patients who did not have an
available echocardiogram were similar to included patients in terms
of mean age (73.9 vs. 73.5 years), proportion of females (41.1% vs.
38.7%), STS-PROM (5.5% vs. 5.3%), and observed in-hospital
mortality (3.2% vs. 3.2%). AR indicates aortic regurgitation; AS,
aortic stenosis; CABG, coronary artery bypass graft surgery; SAVR,
surgical aortic valve replacement; STS-PROM, Society of Thoracic
Surgeons predicted risk of mortality; TTE, transthoracic echocar-
diography.
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accepted cardiovascular prognostic tests, such as the coro-
nary artery calcium scan in primary prevention (increase in
c-statistic, +0.04; IDI, 1.5%).17,18 In the current study, as in
our previous study of patients undergoing isolated CABG,7
measures of LV diastolic dysfunction and RV dysfunction
emerged as the main incremental predictors of postoperative
outcomes. Moreover, measures of LV remodeling and low
mean aortic gradient emerged as strong predictors of
postoperative outcomes in the setting of SAVR, reﬂecting
the deleterious effect of this phenotypic response to chronic
pressure overload.
Consistent with our ﬁndings, Boldt et al. found that
patients with AS often have elevated RV ﬁlling pressures
indicative of subclinical RV dysfunction,19 and Haddad et al.
found that RV MPI assessed by intraoperative trans-
esophageal echocardiography was associated with a higher
incidence of circulatory failure after aortic and mitral valve
surgery.20 Maslow et al. found that RV FAC was associated
with a greater requirement for inotropic or mechanical
support and longer length of stay after CABG.21 The RV MPI
and FAC are recommended by the Guidelines for the Echocar-
diographic Assessment of the Right Heart from the American
Society for Echocardiography12 and have the advantage of (1)
being readily measurable from most routine echocardiography
acquisition protocols and (2) being validated by prognostic
data. Right atrial (RA) dilation was also shown to be predictive,
which is not surprising given that RA size is reﬂective of the
chronicity of underlying RV dysfunction.22
Elevated LV mass is an established predictor of adverse
cardiovascular events,23 which has garnered interest in the
past 5 years as a risk factor in the setting of SAVR. LV mass
reﬂects the severity and chronicity of the pressure overload
caused by AS, as well as adaptive or maladaptive efforts to
remodel in response. Our ﬁndings are consistent with work
from the Cleveland Clinic showing that LV mass was
predictive of late mortality,24 whereas concentric geometry
and small LV cavity size were predictive of early mortality and
prolonged intubation.25 The negative impact of a small LV
cavity size is supported by anecdotal accounts of surgeons
Table 1. Clinical Characteristics
Overall (n=432)
In-Hospital Mortality or Major Morbidity
Yes (n=88) No (n=344)
Age, y 73.510.3 75.510.5 73.010.2
Female, % 167 (38.7) 41 (46.6) 126 (36.6)
BMI, kg/m2 28.86.0 28.76.7 28.85.8
Diabetes, % 157 (36.3) 35 (39.8) 122 (35.5)
Chronic renal disease, % 185 (42.8) 51 (58.0) 134 (39.0)
Chronic lung disease, % 77 (17.8) 21 (23.9) 56 (16.3)
Peripheral vascular disease, % 72 (16.7) 13 (14.8) 59 (17.2)
Cerebrovascular disease, % 74 (17.1) 16 (18.2) 58 (16.9)
Previous myocardial infarction, % 143 (33.1) 36 (40.9) 107 (31.1)
Atrial fibrillation, % 104 (24.1) 24 (27.3) 80 (23.3)
Prior cardiac surgery, % 56 (13.0) 11 (12.5) 45 (13.1)
Heart failure within 2 weeks, % 205 (47.5) 54 (61.4) 151 (33.9)
Charlson comorbidity index 2.21.5 2.61.5 2.01.5
STS-PROM 5.35.1 8.06.9 4.64.3
Aortic prosthesis size, mm 22.42.1 22.32.2 22.42.1
Concomitant coronary bypass, % 219 (50.7) 54 (61.4) 165 (48.0)
Cardiopulmonary bypass time, min 140.659.6 160.474.2 135.554.2
BMI indicates body mass index; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality.
Table 2. In-Hospital Outcomes
Overall (n=432)
Mortality or major morbidity, % 88 (20.4)
Mortality, % 14 (3.2)
Stroke, % 18 (4.2)
Acute kidney injury (RIFLE ≥3), % 25 (5.8)
Prolonged intubation (≥48 hours), % 32 (7.7)
Reoperation, % 47 (10.9)
RIFLE indicates Risk, Injury, Failure, Loss of kidney function, and End-stage kidney
disease.
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Table 3. Preoperative Echocardiographic Parameters
Overall (n=432)
In-Hospital Mortality or Major Morbidity
Yes (n=88) No (n=344)
LVOT diameter, cm 2.10.2 2.10.2 2.10.2
LVOT velocity, cm/s 93.421.8 91.822.1 93.821.8
Peak velocity, cm/s 439.347.3 426.784.7 442.574.7
Peak gradient, mm Hg 79.627.0 75.729.3 80.626.3
Mean gradient, mm Hg 52.718.6 50.020.2 53.418.2
Mean gradient
<40 mm Hg, % 110 (25.5) 26 (29.6) 84 (24.5)
40 to 69 mm Hg, % 246 (57.1) 49 (55.7) 197 (57.4)
≥70 mm Hg, % 75 (17.4) 13 (14.8) 62 (18.1)
Dimensionless index 0.220.07 0.220.07 0.220.06
Aortic valve area, cm2 0.750.22 0.760.24 0.740.21
Aortic valve area index, cm2/m2 0.390.11 0.410.12 0.390.11
Ascending aorta diameter, cm 3.20.5 3.20.5 3.20.5
Bicuspid aortic valve, % 43 (10.5) 6 (7.2) 37 (11.3)
LA volume index, mL/m2 44.017.7 43.217.8 44.217.7
LV end-diastolic volume index, mL/m2 59.520.2 57.420.7 60.020.1
LVEF, % 57.814.3 56.114.9 58.314.1
LVEF
<35%, % 44 (10.2) 10 (11.4) 34 (9.9)
35% to 54%, % 94 (21.9) 27 (30.7) 67 (19.6)
55% to 74%, % 261 (60.7) 45 (51.1) 216 (63.2)
≥75%, % 31 (7.2) 6 (6.8) 57 (7.3)
LV MPI 0.270.16 0.290.16 0.270.16
LV mass index, g/m2 114.732.7 113.135.3 115.132.1
Mean e’ 6.02.0 5.51.7 6.22.0
Mean E/e’ 18.18.5 21.29.9 17.38.0
RA area index, cm/m2 9.42.9 9.72.9 9.42.8
RV end-diastolic area index, cm/m2 8.52.2 8.72.2 8.52.2
RV fractional area change, % 47.011.6 46.813.8 47.111.0
RV MPI 0.410.22 0.480.23 0.390.21
Pulmonary arterial systolic pressure, mm Hg 42.113.3 44.313.7 41.513.1
Mitral regurgitation
None or trivial, % 158 (36.9) 32 (36.4) 126 (37.1)
Mild, % 203 (47.4) 39 (44.3) 164 (48.2)
Moderate, % 65 (15.2) 16 (18.2) 49 (14.4)
Severe, % 2 (0.5) 1 (1.1) 1 (0.3)
Tricuspid regurgitation
None or trivial, % 227 (53.1) 38 (43.2) 178 (54.1)
Mild, % 164 (38.3) 39 (44.3) 125 (38.0)
Moderate, % 34 (7.9) 10 (11.4) 24 (7.3)
Severe, % 3 (0.7) 1 (1.1) 2 (0.6)
LA indicates left atrium; LV, left ventricle; LVEF, left ventricular ejection fraction; LVOT, left ventricular outﬂow tract; MPI, myocardial performance index; RA, right atrium; RV, right ventricle.
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and cardiologists who recall such patients to be “difﬁcult to
manage” and prone to perioperative complications. One
advantage of our study is that we used Simpson’s biplane
method in all patients to measure LV volumes with greater
precision than a single linear dimension.10
The constellation of low mean aortic gradient, small LV
cavity size, and concentric hypertrophy were identiﬁed as
predictors of adverse events; these features are associated
with the phenotype of paradoxical low-gradient severe AS,
which has received considerable attention.26 This phenotype
is often misleading for clinicians because establishing the
diagnosis can be challenging and the prognosis falsely
reassuring given a heart that is not dilated or hypokinetic
(to the contrary, the LV often appears hyperdynamic).
However, studies have convincingly shown, and our data
reafﬁrm, that paradoxical low-gradient AS constitutes a
particularly high-risk group with operative risk of 6% to 33%
and medically treated survival <50% at 3 years.27–30 Patients
with paradoxical low-gradient AS are particularly vulnerable to
the deleterious effects of patient-prosthesis mismatch and,
accordingly, may be good candidates for TAVR.
The evidence for (unrepaired) MR as a risk factor for
mortality after SAVR, as shown in our Cox multivariable
model, is consistent with an analysis from the Johns Hopkins
cardiac surgery database showing that moderate MR was an
independent predictor of long-term mortality after SAVR,
especially when the etiology was organic and the degree of
MR was less likely to improve.31 An analysis from the
PARTNER trial similarly showed that signiﬁcant MR was asso-
ciated with an HR of 1.77 for 2-year mortality post-SAVR.32
Table 5. Optimal Echocardiographic Predictors of 2-Year
Mortality
Unadjusted Adjusted
Odds Ratio (95% CI) Odds Ratio (95% CI)
STS-PROM 1.005 (1.004,
1.007)
1.005 (1.004,
1.007)
LVEF
<35% 2.18 (0.92, 5.20)
35% to 55% 2.08 (1.03, 4.21)
55% to 75% Referent
>75% 2.26 (0.85, 6.07)
LV end-diastolic volume
index
0.66 (0.54, 0.98) 0.54 (0.35, 0.82)
E/e’ 1.51 (1.18, 1.92)
LV mass index 1.00 (0.72, 1.38) 1.38 (1.03, 1.91)
MR grade 1.72 (1.18, 2.52) 1.45 (0.97. 2.16)
LA volume index 1.19 (1.00, 1.69)
RV FAC 0.93 (0.69, 1.25)
RV end-diastolic area index 1.16 (0.87, 1.55)
RV MPI 1.37 (1.11, 1.68)
PASP 1.48 (1.14, 1.91)
TR grade 1.87 (1.31, 2.66)
RA area index 1.70 (1.32, 2.19) 1.28 (0.94, 1.70)
Mean aortic gradient
<40 mm Hg 1.64 (0.85, 3.14) 2.23 (1.04, 4.76)
40 to 70 mm Hg Referent
>70 mm Hg 0.13 (0.48, 2.66)
The unadjusted column represents results from individual logistic regressions, whereas
the adjusted column represents results from one multivariable logistic regression. FAC
indicates fractional area change; LA, left atrium; LV, left ventricle; LVEF, left ventricular
ejection fraction; MPI, myocardial performance index; MR, mitral regurgitation; PASP,
pulmonary artery systolic pressure; RA, right atrium; RV, right ventricle; STS-PROM,
Society of Thoracic Surgeons predicted risk of mortality; TR, tricuspid regurgitant.
Table 4. Optimal Echocardiographic Predictors for In-
Hospital Mortality/Morbidity
Unadjusted Adjusted
Odds Ratio (95% CI) Odds Ratio (95% CI)
STS-PROMM 1.003 (1.002,
1.003)
1.003 (1.002,
1.004)
LVEF
<35% 1.41 (0.65, 3.06)
35% to 55% 1.93 (1.12, 3.35)
55% to 75% Referent
>75% 1.15 (0.45, 2.97)
LV end-diastolic volume
index
0.82 (0.98, 1.01) 0.82 (0.54, 1.00)
E/e’ 1.51 (1.18, 1.92) 1.40 (1.03, 1.78)
LV mass index 1.00 (0.72, 1.38)
MR grade 1.10 (0.84, 1.45)
LA volume index 1.00 (0.70, 1.19)
RV FAC 0.97 (0.77, 1.23)
RV end-diastolic area index 1.16 (0.91, 1.47)
RV MPI 1.44 (1.14, 1.82) 1.25 (0.94, 1.65)
PASP 1.30 (0.87, 1.68)
TR grade 1.32 (0.99, 1.75)
RA area index 1.12 (0.89, 1.43)
Mean aortic gradient
<40 mm Hg 1.24 (0.73, 2.13)
40 to 70 mm Hg Referent
>70 mm Hg 0.84 (0.43, 1.66)
The unadjusted column represents results from individual logistic regressions, whereas
the adjusted column represents results from one multivariable logistic regression. FAC
indicates fractional area change; LA, left atrium; LV, left ventricle; LVEF, left ventricular
ejection fraction; MPI, myocardial performance index; MR, mitral regurgitation; PASP,
pulmonary artery systolic pressure; RA, right atrium; RV, right ventricle; STS-PROMM,
Society of Thoracic Surgeons predicted risk of mortality or major morbidity; TR, tricuspid
regurgitant.
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Despite the impact of MR on mortality, the optimal manage-
ment of such patients with moderate MR undergoing SAVR is
not clear, given that the operative risk of double-valve surgery
continues to be markedly greater than single-valve sur-
gery.33,34
This study had a number of limitations. First, approximately
one half of patients were excluded because they did not have a
digitally available echocardiogram performed at the study
hospitals within the 3-month time frame. The likelihood of
selection bias is low given that included and excluded patients
had nearly identical age, sex, and predicted and observed
mortality. Second, our ﬁndings cannot be directly extrapolated
to patients undergoing TAVR given that these patients were not
included in our cohort. Third, although this is one of the largest
series of SAVR with echocardiographic data, statistical power
to assess short-term mortality remains limited given the rarity
of this occurrence. Fourth, although most of our echocardio-
graphic predictors are routinely measured during a standard
complete exam (mean aortic gradient, LV mass, MR grade, RA
area, and E/e’), some may not be and thus could lengthen the
exam interpretation time by a few minutes (LVEDV, RV MPI).
Fifth, the results remain to be validated in an external cohort of
AVR patients, although it is reassuring to note that the
echocardiographic predictors identiﬁed in this study are
consistent with those identiﬁed in a separate cohort of CABG
patients.7
In conclusion, the preoperative echocardiogram is readily
available and contributes incremental—yet underutilized—
prognostic information than can be added to existing risk
scores. The growing body of evidence from our studies in
CABG and AVR, as well as studies from other groups,
suggests that ﬁndings of LV diastolic dysfunction and RV
function should be incorporated in cardiac surgery risk
prediction models. Furthermore, ﬁndings of elevated LV
mass, small LV cavity size, and low mean aortic gradient
reﬂect the clinical entity of paradoxical low-gradient AS that
confers a high risk of adverse events. Incorporating such
parameters will lead to reﬁned estimates of risk, which, in
turn, will assist clinicians in guiding patients toward the most
appropriate therapeutic pathway.
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